Expanding Liver Transplant Immunosuppression Minimization Via Everolimus (NCT06280950)
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus (CTOT-43)
🩺 Plain-English Summary (8th-Grade Level)
This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of two groups between 2-3 months post-transplant. Seventy participants will be placed into an observational group and will remain on their current post-transplant medications. The duration of the study from time of enrollment is 18-20 months.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Hospital Arizona (Site #: 71144) — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Mayo Clinic Hospital Arizona (Site #: 71144) — Phoenix, Arizona
- University of California, San Francisco (Site #: 71108) — San Francisco, California
- Northwestern University (Site #: 71110) — Chicago, Illinois
- Icahn School of Medicine at Mount Sinai (Site #: 71115) — New York, New York
- Duke University Medical Center (Site #: 71139) — Durham, North Carolina
- University of Pennsylvania (Site #: 71111) — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center (Site #: 71170) — Pittsburgh, Pennsylvania
- Baylor Medical Center (Site #: 71153) — Dallas, Texas
📞 Contact the Study Coordinator
Phone: (301) 761-7414
Email: Tracia.debnam@nih.gov
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Liver Transplant
- Liver Transplantation With Tregs at MGH — Boston, Massachusetts
- OCS Liver Perfusion (OLP) Post-Approval Registry — Birmingham, Alabama
- EVR and EPO for Liver Transplant Tolerance — San Francisco, California
- Biliary Anastomosis in Living Donor Liver Transplant With Amniotic Tissue — Cleveland, Ohio
- Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool — Boston, Massachusetts
- US National OCS Liver Perfusion (OLP) Registry — Birmingham, Alabama
Explore by condition: All Liver Transplant clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.